Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

Early Breast Cancer Trialists’ Collaborative group (EBCTCG)*

Summary
Background Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxicity. We investigated the long-term benefits and risks of adjuvant trastuzumab on breast cancer recurrence and cause-specific mortality.

Methods We did a collaborative meta-analysis of individual patient data from randomised trials assessing chemotherapy plus trastuzumab versus the same chemotherapy alone. Randomised trials that enrolled women with node-negative or node-positive, operable breast cancer were included. We collected individual patient-level data on baseline characteristics, dates and sites of first distant breast cancer recurrence and any previous local recurrence or second primary cancer, and the date and underlying cause of death. Primary outcomes were breast cancer recurrence, breast cancer mortality, death without recurrence, and all-cause mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, oestrogen receptor (ER) status, and trial yielded first-event rate ratios (RRs).

Findings Seven randomised trials met the inclusion criteria, and included 13 864 patients enrolled between February, 2000, and December, 2005. Mean scheduled treatment duration was 14.4 months and median follow-up was 10.7 years (IQR 9.5 to 11.9). The risks of breast cancer recurrence (RR 0.66, 95% CI 0.62 to 0.71; p<0.0001) and death from breast cancer (0.67, 0.61 to 0.73; p<0.0001) were lower with trastuzumab plus chemotherapy than with chemotherapy alone. Absolute 10-year recurrence risk was reduced by 9.0% (95% CI 7.4 to 10.7; p<0.0001) and 10-year breast cancer mortality was reduced by 6.4% (4.9 to 7.8; p<0.0001), with a 6.5% reduction (5.0 to 8.0; p<0.0001) in all-cause mortality, and no increase in death without recurrence (0.4%, –0.3 to 1.1; p=0.35). The proportional reduction in recurrence was largest in years 0–1 after randomisation (0.53, 99% CI 0.46 to 0.61), with benefits persisting through years 2–4 (0.73, 0.62 to 0.85) and 5–9 (0.80, 0.64 to 1.01), and little follow-up beyond year 10. Proportional recurrence reductions were similar irrespective of recorded patient and tumour characteristics, including ER status. The more high risk the tumour, the larger the absolute reductions in 5-year recurrence (eg, 5.7% [95% CI 3.1 to 8.3], 6.8% [4.7 to 9.0], and 10.7% [7.7 to 13.6] in N0, N1–3, and N4+ disease).

Interpretation Adding trastuzumab to chemotherapy for early-stage, HER2-positive breast cancer reduces recurrence of, and mortality from, breast cancer by a third, with worthwhile proportional reductions irrespective of recorded patient and tumour characteristics.

Funding Cancer Research UK, UK Medical Research Council.

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction Amplification of the HER2 gene (also known as ERBB2) is present in 10–20% of tumours in patients with early-stage breast cancer and is associated with aggressive cancers and an increased risk of disease recurrence.1,2 Trastuzumab, a humanised IgG1 monoclonal antibody that targets the extracellular domain of the HER2 protein, improves progression-free survival and overall survival when administered in combination with chemotherapy in HER2-positive metastatic breast cancer.3 Substantial benefits are also seen with trastuzumab added to chemotherapy in non-metastatic breast cancer.4–10 Hence, trastuzumab combined with chemotherapy is now a standard treatment for both metastatic and early-stage, HER2-positive breast cancer.

HER2 status is most reliably ascertained by in-situ hybridisation using probes to label the number of gene copies of HER2 and the chromosome 17 centromere (CEP17), with most trials accepting a HER2 to CEP17 ratio of at least 2.0 as positive.11 Alternatively, immunohistochemical staining of the HER2 protein can be used, with 3+ on a scale of 0, 1+, 2+, and 3+ considered as positive, and in-situ hybridisation used to confirm HER2 status for tumours that are 2+.

However, it is not clear how the level of HER2 amplification, tumour characteristics, in particular oestrogen receptor (ER) status, or other patient risk factors influence the magnitude and duration of treatment benefit. Trastuzumab is expensive and can be associated with cardiac toxicity, particularly when administered with...
Research in context

Evidence before this study
Amplification of the HER2 gene is present in 10–20% of tumours in patients with early-stage breast cancer and is associated with aggressive cancers and an increased risk of disease recurrence. The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)’s ongoing extensive searches of bibliographic databases, including MEDLINE, Embase, the Cochrane Library, and meeting abstracts, up to March 31, 2020, identified seven trials comparing chemotherapy plus trastuzumab, a humanised IgG1 monoclonal antibody that targets the extracellular domain of the HER2 protein, with the same chemotherapy alone for early-stage, HER2-positive breast cancer. Individual trials reported substantial benefits with trastuzumab; however, cardiac toxicity was increased and it was unclear how the level of HER2 amplification, tumour characteristics (eg, oestrogen receptor [ER] status), or other patient risk factors influence the magnitude and duration of benefit.

Methods
Study design and participants
Methods of identifying trials, data collection, checking, analysis, and presentation for this collaborative meta-analysis of individual patient-level data are as described in previous EBCTCG reports, and conform to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (Individual Patient Data).

Trials were eligible if they began before Jan 1, 2010, and randomly assigned women with node-negative or node-positive, operable breast cancer to either chemotherapy (adjuvant or neoadjuvant) plus trastuzumab or to the same chemotherapy alone. Trials of trastuzumab added to other biological therapies (eg, trials comparing lapatinib, pertuzumab, or neratinib with or without trastuzumab) were not eligible. The lead investigators of all identified, eligible trials were asked during 2016–19 to supply individual patient-level data from 13 864 women in seven randomised controlled trials. Trastuzumab reduced the rate of breast cancer recurrence by 34% and of breast cancer mortality by 33%, compared with chemotherapy alone. The average absolute reduction in the 10-year risk of breast cancer recurrence was 9.0%, with a 6.4% reduction in the 10-year risk of dying from breast cancer, and no increase in deaths unrelated to breast cancer. The proportional reductions in recurrence were similar for ER-positive and ER-negative tumours, and did not differ significantly by other patient or tumour characteristics, including the level of HER2 amplification, for patients considered to be HER2-positive.

Implications of all the available evidence
Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces recurrence of and mortality from breast cancer by a third, with worthwhile proportional benefits irrespective of recorded patient and tumour characteristics.

Added value of this study
This collaborative meta-analysis collated, checked, and analysed individual patient-level data from 13 864 women in seven randomised controlled trials. Trastuzumab reduced the rate of breast cancer recurrence by 34% and of breast cancer mortality by 33%, compared with chemotherapy alone. The average absolute reduction in the 10-year risk of breast cancer recurrence was 9.0%, with a 6.4% reduction in the 10-year risk of dying from breast cancer, and no increase in deaths unrelated to breast cancer. The proportional reductions in recurrence were similar for ER-positive and ER-negative tumours, and did not differ significantly by other patient or tumour characteristics, including the level of HER2 amplification, for patients considered to be HER2-positive.

anthracyclines. In this meta-analysis, we aimed to evaluate the long-term benefits and risks of trastuzumab on breast cancer recurrence and cause-specific mortality, and whether these effects vary by patient characteristics or types of tumour.

Methods
Study design and participants
Methods of identifying trials, data collection, checking, analysis, and presentation for this collaborative meta-analysis of individual patient-level data are as described in previous EBCTCG reports, and conform to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (Individual Patient Data).

Trials were eligible if they began before Jan 1, 2010, and randomly assigned women with node-negative or node-positive, operable breast cancer to either chemotherapy (adjuvant or neoadjuvant) plus trastuzumab or to the same chemotherapy alone. Trials of trastuzumab added to other biological therapies (eg, trials comparing lapatinib, pertuzumab, or neratinib with or without trastuzumab) were not eligible. The lead investigators of all identified, eligible trials were asked during 2016–19 to supply information for each individual patient on randomisation date; allocated treatment; age; menopausal status; body-mass index (BMI); tumour diameter, grade, histology, and spread to loco-regional lymph nodes; ER, progesterone receptor (PR), and HER2 receptor test scores; cell proliferation (Ki-67); dates and sites of first distant breast cancer recurrence and any previous local recurrence or second primary cancer; and the date and underlying cause of death.

Primary outcomes were any recurrence of invasive breast cancer (distant, loco-regional, or new primary in the contralateral breast), breast cancer mortality, death without recurrence, and all-cause mortality. Prespecified primary subgroup investigations were by site of recurrence; concurrent or sequential trastuzumab and chemotherapy; level of HER2 amplification; age; ER status; PR status; nodal status; tumour diameter, grade, histology (ie, ductal or lobular); BMI; proliferation index (Ki-67 <10%, 10–19%, or ≥20%); and follow-up period (years 0–1, 2–4, 5–9, ≥10).

Statistical analysis
Statistical methods for checking and analysing data are described in previous EBCTCG reports, and in the statistical analysis plan (appendix). Time-to-event analyses were stratified by age, ER status, trial, and, except for studies including neoadjuvant trastuzumab, nodal status. Each analysis compared all women randomly assigned, regardless of treatment compliance (yielding intention-to-treat analyses). Log-rank statistics were used to estimate the ratio of the annual event rates in the trastuzumab and control groups and its confidence interval; 95% CIs were used for meta-analyses and 99% CIs were used for individual trials or subgroups. Breast cancer mortality rate ratios (RRs) were estimated by subtracting log-rank statistics for mortality without recurrence from those of overall mortality, which avoids the need to identify which deaths after recurrence were from breast cancer. Forest plots and Kaplan-Meier graphs describe the separate trials and their combined results, and tests for heterogeneity explore whether proportional risk reductions vary by trial, or by patient or tumour-related characteristics. Sensitivity
analyses to investigate the effect of crossover to trastuzumab censored all women in the HERA trial on the date when crossover to trastuzumab was offered to control patients. Statistical analyses used in-house FORTRAN programmes.

Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results
Individual patient-level data were obtained from all seven identified, relevant trials (table), providing data for 13864 women with early-stage, HER2-positive breast cancer who had been randomly assigned to receive chemotherapy plus trastuzumab or chemotherapy alone between February, 2000, and December, 2005. Of these women, 3685 (26·6%) had breast cancer recurrence. 2738 (19·7%) deaths occurred, of which 347 (12·7%) were from causes unrelated to breast cancer and without recorded disease recurrence. Median follow-up was 10·7 years (IQR 9·5–11·9). Trial inclusion criteria were HER2-positive tumours, with most trials requiring that these should be either lymph node-negative or high-risk if node-negative (generally defined as grade 3, tumour >1 cm if ER-negative or >2 cm if ER-positive; table). HER2 status was based on local immunohistochemistry or fluorescence in-situ hybridisation testing, with some studies requiring central laboratory confirmation.

Sequential 12-week anthracycline followed by 12-week taxane chemotherapy regimens were used in the NSABP trial B-31 (2119 [15·3%] of 13864 patients), NCCTG trial N9831 (3505 [25·3%]), and BCIRG 006 trial (2147 [15·5%]). Patients in the NOAH trial (235 [1·7%] patients) were given concurrent taxane and anthracycline, then taxane alone followed by cyclophosphamide–methotrexate–fluorouracil. FinHER (231 [1·7%] patients) included a randomisation to docetaxel or vinorelbine before anthracyclines, and PACS 04 (528 [3·8%] patients) randomly assigned patients to fluorouracil–epirubicin–cyclophosphamide or to epirubicin plus docetaxel. The choice of chemotherapy was not mandated in the HERA study (5099 [36·8%] patients), with 94% receiving anthracyclines and 26% receiving a taxane in addition to an anthracycline. BCIRG 006 included a non-anthra-cycline (docetaxel–carboplatin–trastuzumab) group, which was excluded from the main analyses as there was no control group receiving the same chemotherapy. Comparing the docetaxel–carboplatin–trastuzumab group with the anthracyline and docetaxel control group would have shown similar benefits from adding trastuzumab as those in the included trials (appendix p 20). In all trials, endocrine therapy was recommended in hormone receptor-positive disease.

Except for the NOAH trial, chemotherapy plus trastuzumab was administered after surgery. In HERA, PACS-04, and one group in NCCTG trial N9831, trastuzumab was commenced after completion of all chemotherapy. In other trials, trastuzumab was started after any anthracycline courses and given concurrently with taxane (or vinorelbine for 120 [52%] of FinHER patients) chemotherapy. Duration of treatment was 12 months in all trials except for FinHER, which tested 9 weeks of trastuzumab. The HERA trial also included a 24-month trastuzumab treatment group, which was included in the primary analyses of trastuzumab (any duration) versus no trastuzumab. Thus, mean scheduled treatment duration across all trials was 14·4 months. Following presentation of early analyses in June, 2005, 884 (52·1%) patients in the control group of HERA and 382 (36·0%) patients in the control group of NSABP trial B-31 crossed over to receive trastuzumab (at median periods of 23 months from randomisation for HERA and 17 months for NSABP trial B-31). There were few crossovers in the other trials.

Figure 1 shows the year started, study name, treatment comparison, log-rank statistics, and the ratio of annual event rates for each trial. Pooled analysis of all trials found a highly significant reduction in recurrence (RR 0·66, 95% CI 0·62–0·71; p<0·0001; figure 1) and breast cancer mortality (0·67, 0·61 to 0·73; p<0·0001; appendix p 7) with chemotherapy plus trastuzumab compared with chemotherapy alone. There was no significant heterogeneity between the seven trial results for recurrence or breast cancer mortality (p=0·21). The average absolute reduction in 10-year risk of recurrence was 9·0% (95% CI 7·4 to 10·7; p<0·0001) with a 6·4% (4·9 to 7·8; p<0·0001) reduction in 10-year breast cancer mortality, a 6·5% (5·0 to 8·0; p<0·0001) reduction in all-cause mortality, and no increase in death without recurrence (0·4%, –0·3 to 1·1; p=0·35; figure 2; appendix pp 3–11). Subgroup analyses of breast cancer recurrence (local or distant, excluding contralateral), distant recurrence, and breast cancer mortality are shown in figure 3 and the appendix (pp 15–17). Trastuzumab reduced distant recurrence (RR 0·63, 99% CI 0·57 to 0·70) and local recurrence (0·72, 0·59 to 0·89), but not contralateral breast cancer incidence (0·93, 0·68 to 1·26; figure 3). There was little or no reduction in the incidence of brain metastases as the first site of distant recurrence (RR 0·91, 95% CI 0·73 to 1·13; p=0·40), a significantly lesser effect of trastuzumab than on distant recurrence at other sites (0·60, 0·55 to 0·65; p<0·0001; appendix p 18).

The largest proportional reduction in recurrence was in years 0–1 (RR 0·53, 99% CI 0·46–0·61) with smaller proportional reductions in years 2–4 (0·73, 0·62–0·85) and years 5–9 (0·80, 0·64–1·01), and little follow-up beyond year 10 (figure 3). There were similar proportional reductions in risk of recurrence for ER-negative and ER-positive cancers (RR 0·62, 95% CI 0·56–0·69 vs 0·67,
| Trial | Years of recruitment | Number of patients | Key participant eligibility criteria | Median age (QR), years | Nodal status* | Tumour size | Tumour grade | ER status | HER2:CEP17 ratio | Median follow-up, years (IQR) |
|-------|----------------------|--------------------|--------------------------------------|------------------------|--------------|-------------|-------------|-----------|----------------|-----------------------------|
| FinHER trial (Joensuu et al, 2009) | 2000-03 | 231 | Aged ≥65 years, HER2-positive; node-positive or node-negative cancer with tumour size >2 cm and negative staining for PR | 50 (25–65) | 16% N0; 32% N1-3; 52% N4+ | 7% T1a+b; 28% T1c; 8% T2; 6% T3 or T4; 1% unknown | 2% well differentiated; 31% moderate; 64% poor; 3% unknown | 53% ER-negative; 47% ER-positive | No data | 10.7 (10-13.4) |
| NSABP trial B-31 (Romond et al, 2005) | 2000-05 | 2119 | Aged ≥18 years, HER2-positive; node-negative disease | 49 (22–78) | 57% N1-3; 43% N4+ | 8% T1a+b; 32% T1c; 50% T2; 9% T3 or T4; 1% unknown | 2% well differentiated; 29% moderate; 68% poor; 1% unknown | 47% ER-negative; 53% ER-positive | No data | 9.4 (8.1–10.8) |
| NCCTG trial N9831 (Romond et al, 2005) | 2000-05 | 3595 | Aged ≥18 years, HER2-positive; node-positive or high-risk node-negative disease defined as tumour size >2 cm and positive ER or PR, or tumour size >1 cm and negative ER and PR | 50 (19–82) | 13% N0; 29% N1-3; 40% N4+; 8% unknown | 7% T1a+b; 32% T1c; 52% T2; 9% T3 or T4 | 2% well differentiated; 27% moderate; 70% poor; 1% unknown | 47% ER-negative; 53% ER-positive | No data | 12.8 (11-14.2) |
| HERA trial (Piccart-Gebhart et al, 2005) | 2001-05 | 5099 | Aged ≥18 years, HER2-positive; node-negative disease (irrespective of pathological tumour size) or node-negative disease if tumour size >1 cm on pathological examination | 49 (18-79) | 32% N0; 29% N1-3; 8% N4+; 11% unknown | 5% T1a+b; 34% T1c; 44% T2; 5% T3 or T4; 12% unknown | 2% well differentiated; 32% moderate; 61% poor; 5% unknown | 51% ER-negative; 49% ER-positive | No data | 0-1.9; 8%; 2.0-3.4; 12%; 4.0-5.4; 5%; 6.0-7.4; 16%; 7.5-9.9; 17%; 10.0-11.9; 20%; unknown: 28% |
| PACS 04 (D’Hondt et al, 2019) | 2001-04 | 528 | Aged 18–65 years, HER2-positive; node-negative disease | 49 (22–65) | 58% N1-3; 42% N4+ | 7% T1a+b; 38% T1c; 48% T2; 7% T3 or T4 | 3% well differentiated; 31% moderate; 65% poor; 1% unknown | 44% ER-negative; 56% ER-positive | No data | 9.6 (8.0–10.1) |
| BORG 006 trial (Slamon et al, 2011) | 2001-04 | 2147 | Aged 18–70 years, HER2-positive; node-positive or high-risk node-negative disease defined as invasive adenocarcinoma with either 0 (pN0) among a minimum of six resected lymph nodes or negative sentinel node biopsy (pN0) and at least one of the following: tumour size >2 cm, negative ER, PR, or both; grade 2-3; or aged ≥55 years | 49 (22-74) | 29% N0; 38% N1-3; 33% N4+ | 7% T1a+b; 32% T1c; 54% T2; 6% T3 or T4 | 2% well differentiated; 29% moderate; 65% poor; 4% unknown | 51% ER-negative; 49% ER-positive | 2.0-3.4; 10%; 3.5-4.9; 13%; 5.0-7.4; 26%; 7.5-9.9; 21%; ≥10.0; 29%; unknown: 3% |
| NOAH trial (Gianni et al, 2010) | 2002-05 | 235 | Aged ≥18 years, HER2-positive; suitable for neoadjuvant chemotherapy | 51 (25–81) | 15% N0; 85% N+ | No data | No data | 69% ER-negative; 31% ER-positive | No data | 5.8 (4.8–6.7) |

* Nodal status recorded at the time of surgery, except for the NOAH trial, which gave trastuzumab with neoadjuvant chemotherapy in addition to giving trastuzumab after surgery. ER=oestrogen receptor. PR=progesterone receptor. All trials administered chemotherapy and trastuzumab after surgery, except for the NOAH trial, which gave trastuzumab with neoadjuvant chemotherapy in addition to giving trastuzumab after surgery. ER=oestrogen receptor. PR=progesterone receptor. * Nodal status recorded at the time of surgery, except for the NOAH trial, which gave trastuzumab with neoadjuvant chemotherapy in addition to giving trastuzumab after surgery. ER=oestrogen receptor. PR=progesterone receptor. All trials administered chemotherapy and trastuzumab after surgery, except for the NOAH trial, which gave trastuzumab with neoadjuvant chemotherapy in addition to giving trastuzumab after surgery. ER=oestrogen receptor. PR=progesterone receptor. All trials administered chemotherapy and trastuzumab after surgery.
In three trials, individual patient HER2 to CEP17 ratios were available from central pathology fluorescence in-situ hybridisation tests, with tumours with a ratio of at least 2.0 deemed to be HER2-positive. Figure 3 shows the reductions in risk of recurrence subdivided by finer categories of the HER2 to CEP17 ratio, suggesting no effect in the few patients with HER2 to CEP17 ratios of less than 2.0, and no significant trend of increasing benefit with increasing HER2 to CEP17 ratios above this threshold.

Figure 5 shows the 5-year risk of recurrence in different nodal status groups. Although the proportional reduction was similar across groups, the absolute reduction in 5-year risk was greatest in patients with more involved nodes (5.7%, 95% CI 3.1–8.3 in N0; 6.8%, 4.7–9.0 in N1–3; and 10.7%, 7.7–13.6 in ≥N4 disease) because of their higher absolute risk of recurrence.

The reduction in recurrence in trials that administered trastuzumab concurrently with chemotherapy did not differ significantly from that in trials where it was given sequentially after completion of chemotherapy (RR 0.61, 99% CI 0.53–0.70 for concurrent trastuzumab vs 0.69, 0.61–0.78 for sequential trastuzumab; heterogeneity p=0.083; figure 3). In HERA, the largest sequential treatment trial, trastuzumab was offered to control patients, which might have attenuated the benefits of trastuzumab. In sensitivity analyses censoring all women in the HERA trial on the date when crossover to trastuzumab was offered to control patients, the average absolute improvement in 10-year recurrence risk with at least 2.0 deemed to be HER2-positive. Figure 3 shows the reductions in risk of recurrence subdivided by finer categories of the HER2 to CEP17 ratio, suggesting no effect in the few patients with HER2 to CEP17 ratios of less than 2.0, and no significant trend of increasing benefit with increasing HER2 to CEP17 ratios above this threshold.

Figure 5 shows the 5-year risk of recurrence in different nodal status groups. Although the proportional reduction was similar across groups, the absolute reduction in 5-year risk was greatest in patients with more involved nodes (5.7%, 95% CI 3.1–8.3 in N0; 6.8%, 4.7–9.0 in N1–3; and 10.7%, 7.7–13.6 in ≥N4 disease) because of their higher absolute risk of recurrence.

The reduction in recurrence in trials that administered trastuzumab concurrently with chemotherapy did not differ significantly from that in trials where it was given sequentially after completion of chemotherapy (RR 0.61, 99% CI 0.53–0.70 for concurrent trastuzumab vs 0.69, 0.61–0.78 for sequential trastuzumab; heterogeneity p=0.083; figure 3). In HERA, the largest sequential treatment trial, trastuzumab was offered to control patients, which might have attenuated the benefits of trastuzumab. In sensitivity analyses censoring all women in the HERA trial on the date when crossover to trastuzumab was offered to control patients, the average absolute improvement in 10-year recurrence risk with at least 2.0 deemed to be HER2-positive. Figure 3 shows the reductions in risk of recurrence subdivided by finer categories of the HER2 to CEP17 ratio, suggesting no effect in the few patients with HER2 to CEP17 ratios of less than 2.0, and no significant trend of increasing benefit with increasing HER2 to CEP17 ratios above this threshold.

Figure 5 shows the 5-year risk of recurrence in different nodal status groups. Although the proportional reduction was similar across groups, the absolute reduction in 5-year risk was greatest in patients with more involved nodes (5.7%, 95% CI 3.1–8.3 in N0; 6.8%, 4.7–9.0 in N1–3; and 10.7%, 7.7–13.6 in ≥N4 disease) because of their higher absolute risk of recurrence.

The reduction in recurrence in trials that administered trastuzumab concurrently with chemotherapy did not differ significantly from that in trials where it was given sequentially after completion of chemotherapy (RR 0.61, 99% CI 0.53–0.70 for concurrent trastuzumab vs 0.69, 0.61–0.78 for sequential trastuzumab; heterogeneity p=0.083; figure 3). In HERA, the largest sequential treatment trial, trastuzumab was offered to control patients, which might have attenuated the benefits of trastuzumab. In sensitivity analyses censoring all women in the HERA trial on the date when crossover to trastuzumab was offered to control patients, the average absolute improvement in 10-year recurrence risk with at least 2.0 deemed to be HER2-positive. Figure 3 shows the reductions in risk of recurrence subdivided by finer categories of the HER2 to CEP17 ratio, suggesting no effect in the few patients with HER2 to CEP17 ratios of less than 2.0, and no significant trend of increasing benefit with increasing HER2 to CEP17 ratios above this threshold.

Figure 5 shows the 5-year risk of recurrence in different nodal status groups. Although the proportional reduction was similar across groups, the absolute reduction in 5-year risk was greatest in patients with more involved nodes (5.7%, 95% CI 3.1–8.3 in N0; 6.8%, 4.7–9.0 in N1–3; and 10.7%, 7.7–13.6 in ≥N4 disease) because of their higher absolute risk of recurrence.

The reduction in recurrence in trials that administered trastuzumab concurrently with chemotherapy did not differ significantly from that in trials where it was given sequentially after completion of chemotherapy (RR 0.61, 99% CI 0.53–0.70 for concurrent trastuzumab vs 0.69, 0.61–0.78 for sequential trastuzumab; heterogeneity p=0.083; figure 3). In HERA, the largest sequential treatment trial, trastuzumab was offered to control patients, which might have attenuated the benefits of trastuzumab. In sensitivity analyses censoring all women in the HERA trial on the date when crossover to trastuzumab was offered to control patients, the average absolute improvement in 10-year recurrence risk with
trastuzumab increased from 9.0% to 10.6% (appendix p 21). To minimise the effects of crossover, we compared the recurrence reductions seen with concurrent versus sequential trastuzumab in years 0–4 from randomisation, which showed a significantly larger reduction with concurrent treatment than with sequential treatment (p=0.02; appendix p 22). This indirect comparison is supported by the direct randomised comparison between concurrent and sequential trastuzumab in the NCCTG trial N9831, in which there were fewer distant recurrences (RR 0.78, 95% CI 0.63–0.97; p=0.026) and breast cancer deaths (0.76, 0.60–0.96, p=0.023) with concurrent trastuzumab than with sequential trastuzumab (appendix pp 23–24).

Overall, there was no apparent increase in deaths without breast cancer recurrence in the trastuzumab group (RR 0.90, 95% CI 0.72–1.12; p=0.35; appendix p 19). Similarly, there was no apparent increase in cardiovascular mortality (RR 1.23, 95% CI 0.73–2.06; p=0.44) or in deaths from new cancers at sites other than the breast (0.79, 0.54–1.17; p=0.24). However, there were more deaths unrelated to breast cancer in the first...
Figure 3: Subgroup analyses of the effect of trastuzumab
All analyses, except for site of first recurrence, include any loco-regional or distant recurrence but exclude contralateral disease. ER=oestrogen receptor. PR=progesterone receptor.
year with chemotherapy plus trastuzumab than with chemotherapy alone (0·37% [31/8299] vs 0·16% [13/8328]; RR 2·15, 95% CI 1·11–4·14; p=0·023; appendix p 8). No particular cause of death explained this excess (appendix p 19). Of the 414 deaths without recorded recurrence, 72 (17%) were from unknown causes; however, these were unrelated to treatment allocation or TNM stage (appendix p 19). Of the 414 deaths without recorded particular cause of death explained this excess (appendix p 8). No fatal toxic events were reported with no excess in the group than in the control group, but the proportion of patients affected was low (appendix pp 26–29). Few toxic events were reported with no excess in the trastuzumab group (appendix pp 26–29).

**Discussion**

This meta-analysis substantiates that—for patients with operable HER2-positive breast cancer—the addition of trastuzumab to chemotherapy further reduces recurrence of, and mortality from, breast cancer during the first decade of follow-up by about a third. For the patient population in the trials in this analysis, this finding translates, on average, into a 10-year absolute reduction of 9·0% in recurrence and of 6·4% in breast cancer mortality, compared with chemotherapy alone. These reductions were achieved despite substantial crossover from control to trastuzumab in two trials; therefore, the benefits might have been larger with perfect compliance. The greatest effect was on distant recurrence, although local recurrence was also reduced; however, there was no apparent effect on the incidence of new contralateral breast cancers.

Subgroup analyses by conventional pathological features indicated similar proportional reductions in recurrence, irrespective of nodal status, tumour grade, tumour diameter, and histological subtype. Trastuzumab produced similar proportional reductions in recurrence of ER-positive and ER-negative disease, as did chemotherapy alone in previous meta-analyses. Similar to HER2-negative disease, the risk of early (years 0–4) recurrence was higher for HER2-positive, ER-negative tumours than for HER2-positive, ER-positive tumours. However, late (years 5–9) recurrences are more likely in ER-positive than in ER-negative disease, even though patients with ER-positive disease were scheduled to receive at least 5 years of endocrine therapy. As the proportional reductions in different subgroups were similar, there were greater absolute reductions in risk among patients with node-positive disease than among those with node-negative disease because of their higher absolute risk of recurrence. Nevertheless, the absolute benefits were substantial, even in the patients with node-negative disease entered into these trials, suggesting...
appreciable benefits from the addition of trastuzumab to chemotherapy for all patients with HER2-positive disease fit enough to receive systemic treatment.

Only three studies included central fluorescence in-situ hybridisation testing and, in these, benefits from trastuzumab did not increase with increasing HER2 to CEP17 ratio above the conventional cutoff of 2·0. There was no apparent benefit in tumours with HER2 to CEP17 ratios below the 2·0 threshold for HER2 positivity, consistent with the reduced efficacy of trastuzumab in low HER2 tumours in the NSABP trial B-47; however, there were not enough patient numbers to assess whether, for example, 1·8 or 2·2 might be a better cutoff for HER2 positivity than might 2·0.

Starting trastuzumab concurrently with the taxane component of chemotherapy seemed at least as efficacious as giving it sequentially (ie, starting only after completing all chemotherapy), which is consistent with data suggesting that giving trastuzumab concurrently with chemotherapy is synergistic. Sequential administration does allow for assessment of cardiac function (an eligibility requirement for HERA) following chemotherapy; however, in patients for whom cardiac risk is not a major concern, giving trastuzumab concurrently with
the taxane cycles seems to be advisable given that benefits emerge early: the biggest impact on recurrence was seen in the first 2 years after randomisation and there was no apparent increase in toxicity with concurrent taxane chemotherapy and trastuzumab, compared with sequential treatment.

We found no overall increase in mortality from causes unrelated to breast cancer. Nevertheless, there were more deaths without recurrence in the first year after randomisation with trastuzumab than with control, which was not explained by administering trastuzumab concurrently with chemotherapy. This finding could well be due to chance, as the difference is spread over several different causes. However, even if the apparent excess risk is real, the excess number of these deaths was 30 times smaller than the number of deaths from breast cancer prevented. Despite the well documented adverse effects of trastuzumab on cardiac function, the number of deaths from cardiovascular causes was low and not significantly higher in patients treated with chemotherapy plus trastuzumab than in those treated with chemotherapy alone, neither overall nor in the first year. Longer follow-up of these trials is needed to evaluate safety more than 10 years after treatment. Individual patient-level data on non-fatal toxicity, including cardiac morbidity, was not available for this meta-analysis, but data from individual trial reports indicate that serious toxicity is rare, even though most trials administered trastuzumab after anthracycline chemotherapy regimens. Although more effective, this type of regimen is associated with greater toxicity than is non-anthracycline chemotherapy.22,23

The incidence of non-breast second primary cancers did not appear to be reduced by trastuzumab, indicating that the reduced incidence of such cancers in the initial NSABP trial B-31 and the NCCTG trial N9831 report might have been a chance finding.

Most trials in this meta-analysis treated patients with trastuzumab for 12 months and the recurrence reductions were largest during this treatment period. Somewhat less benefit was found during years 2—4 and 5—9, after any trastuzumab treatment had been completed, raising the possibility that extended treatment with trastuzumab might have been more efficacious. Nevertheless, in the HERA trial, 2 years of trastuzumab did not appear to provide any greater benefit than 1 year of treatment.24 Switching to another HER2-directed therapy, neratinib, after 1 year of trastuzumab appeared more effective than continuing trastuzumab.25 We could not compare the efficacy of trastuzumab for 1 year versus less than 1 year as only the FinHER trial tested a shorter treatment time of 9 weeks. We included this small trial in these analyses, even though this treatment duration appears inadequate.26 However, the overall results would not be materially different if it were excluded. Three trials comparing 1 year versus 6 months of trastuzumab treatment, which were not included in this meta-analysis, all reported fewer recurrences with 12 months than with 6 months of trastuzumab, but had conflicting interpretations as to whether or not 12 months of treatment was more effective than 6 months.24—26 Despite these trials not being included in our main analysis, we did a post-hoc meta-analysis of their published results, which showed fewer recurrences with 12 months than with 6 months of trastuzumab (appendix p 30); however, an individual patient-level data meta-analysis of these trials is needed to help clarify the benefits and risks of extended trastuzumab treatment.

The efficacy of trastuzumab could be enhanced by adding other HER-directed therapies, such as lapatinib or pertuzumab,27—28 and by giving combination HER2-directed therapy before surgery.29 Adapting treatment according to initial tumour response is another approach, as in the KATHERINE trial, in which switching to trastuzumab–emtansine (an antibody–drug conjugate) was more effective than continuing trastuzumab in patients with residual disease following neoadjuvant chemotherapy plus trastuzumab.29 Further understanding of how cancer biology affects outcome, such as the relevance of tumour-infiltrating lymphocytes or tumour genomics,30 might also help to individualise treatment approaches.

In summary, this meta-analysis confirms that breast cancer recurrence and mortality can be reduced by a third by adding 1 year of trastuzumab treatment to adjuvant chemotherapy in patients with early-stage, HER2-positive breast cancer. The proportional reduction was unaffected by any of the measured tumour or patient characteristics. Because optimal anthracyline and taxane-based chemotherapy schedules also reduce the risk of breast cancer mortality by about a third, regardless of HER2 status or other characteristics,12,17 the combination of chemotherapy plus trastuzumab for HER2-positive breast cancer could reduce the risk of death from breast cancer by about 50%, compared with receiving neither chemotherapy nor trastuzumab.

Contributors
The EBCTCG secretariat was responsible for maintaining collaboration, identifying trials, and obtaining and checking datasets. R Bradley, J Braybrooke, and R Gray designed and carried out the analyses. R Bradley and R Gray accessed and verified the data. R Gray, R Bradley, J Braybrooke, and Z Liu drafted the report. All writing committee members contributed to revising the report. Interim analyses were discussed by the steering committee and trialists who supplied data for the analysis. The EBCTCG secretariat had full access to all the data in the study and the writing committee had final responsibility for the decision to submit for publication.

Writing committee
R Bradley, J Braybrooke, R Gray, R Hills, Z Liu, R Peto, L Davies, D Dodwell, P McGale, H Pan, C Taylor (Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK); S Anderson (Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA); R Gelber (Harvard T H Chan School of Public Health, Boston, MA, USA); L Gianni (Fondazione ‘Gianni Bonadonna’, Milan, Italy); W Jacot (Institut Curie Montpellier, Montpellier, France); H Joensuu (Helsinki University Hospital, Helsinki, Finland); A Moreno-Aspitia (Mayo Clinic, Jacksonville, FL, USA); M Piccart (Institut Jules Bordet, Brussels, Belgium); M Press (University of Southern California, Los Angeles, CA, USA); E Romond (University of Kentucky, Lexington, KY, USA).

www.thelancet.com/oncology Vol 22 August 2021
Articles

D Slamon (David Geffen School of Medicine at UCLA, Los Angeles, CA, USA); V Suman (Mayo Clinic, Rochester, MN, USA); D Cameron (University of Edinburgh, Edinburgh, UK); Berg (Karasjok Institute and University Hospital, Stockholm, Sweden); K J Pritchard (Sunnybrook Odette Cancer Centre, Toronto, ON, Canada); S Swain (Georgetown University Medical Center, Washington, DC, USA).

EBCCTG secretariat
R Berry, C Boddington, R Bradley, J Braybrooke, M Clarke, C Davies, L Davies, D Dodwell, D Fruane, D Evans, J Gay, L Gettins, J Godwin, R Gray, R Hills, S James, H Liu, Z Liu, E MacKinnon, G Manusu, P McGale, T McGHugh, P Morris, H Pan, R Pet, S Read, E Stratton, C Taylor, and Y Wang.

Groups (lead investigators) providing data
Breast Cancer International Research Group (BCIRG)/Translational Research in Oncology (TRIO), USA (J Crown, H Fung, M Press, D Slamon); Finnish Breast Cancer Group, Finland (H Joensuu); Herceptin-Adjuvant (HERA)/Breast International Group (BIG), (D Cameron, E de Azambuja, R Gelber, M Piccart, M Regan); Northern Central Clinical Trial Group (NCCCTG), USA (A Moreno-Aspitia, V Suman); Fondazione Michelangelo, Milan, Italy (L Gianni, P Valagussa); National Surgical Adjuvant Breast and Bowel Project (NSABP), USA (S Anderson, C Geyer, E Mamounas, E Romond, S Swain, N Wolmark); Project Adjuvant on the Cancer de Sein 04 (PACS-04), France (S Delaloge, W Jacot, M Spielmann).

EBCCTG steering committee
J Bergh, K J Pritchard, S Swain (co-chairs), D Cameron (vice-chair), K Albain, S Anderson, R Arriagada, J Bartlett, E Bergsten-Nordström, J Bliss, R Bradley, E Brain, J Braybrooke*, I Carey, M Clarke*, R Coleman, J Coutie, N Davidson, L De Mastro, A Di Leo, J Dignam, D Dodwell, D Fruane, D Evans, I Elbertsen, P Francis, R Gelber, M Grant, M Goetz, P Goodwin, R Gray, P Halpin-Murphy, D Hayes, C Hill, R Jagsi, W Janni, Z Liu*, S Loeb, M Kimm*; E Mamounas, G Manusu*, M Martin, P McGale*, H Muki, V Nekludova, I Norton, Y Ohashi, H Pan*, R Pet*, M Piccart, I Pierce, P Poortmans, V Raina, D Rea, M Regan, J Robertson, E Rutgers, D Slamon, T Spanic, J Sparano, G Steger, C Taylor*, G Tang, M Tiu, A Titt*, G Viale, X Wang, T Whelan, N Wülken, N Wolmark*. *EBCCTG Secretariat, Clinical Trial Service Unit, Nuffield Department of Population Health.

Declaration of interests
RB and RGR report that EBCCTG is supported by a programme grant from Cancer Research UK. Additional support was received from core funding from the UK Medical Research Council to Nuffield Department of Population Health, University of Oxford. RGR reports institutional grants or contracts from Roche, Novartis, Pfizer, AstraZeneca, and Merck. LG reports institutional grants or contracts and consulting fees from F. Hoffmann-La Roche, Genentech, Amgen, Merck, Pfizer, Taiho Pharmaceutical, Hexal Sandoz, Seattle Genetics, Synthon, Zymeworks, and Sanofi-Aventis; and acting as chair at European Medicines Agency for the Scientific Advisory Board in Oncology—Haematology 2016–2020. KIP reports support from Roche–Genentech and Sanofi; grants or contracts, consulting fees, and support for attending meetings and travel from Pfizer; grants or contracts, and consulting fees from Novartis and Bayer; grants or contracts from Syndax, Millennium Pharmaceuticals, Aileron Therapeutics, and Genentech; and consulting fees from Eli Lilly. SS reports a position on the Board of Directors for BioMarin and stock or stock options from BioMarin, Amgen, Seattle Genetics, and Pfizer. D Cameron reports consulting fees (paid to employer) from Roche Diagnostics. JBe reports institutional support for clinical studies and spin-off projects on molecular markers from Amgen, Bayer, AstraZeneca, Merck, Roche, and Sanofi-Aventis; and acting as chair at European Medicines Agency for the Scientific Advisory Board in Oncology—Haematology 2016–2020. KIP reports royalties or licences from UpToDate; and participation on a Data Safety Monitoring Board or Advisory Board for Pfizer. SS reports grants or contracts, paid non-promotional speaking or advisory boards, support for attending meetings and travel, third party writing, and unpaid membership of steering committee Kaitlin and Impassion 132 from Genentech–Roche. SS also reports grants or contracts from Kailos Genetics; paid non-promotional speaking or advisory boards from Daichi-Sankyo, Molecular Templates, Tocagen, Silverback Therapeutics, Eli Lilly, Beijing Medical Foundation, Pieris Pharmaceuticals, Exact Sciences (Genomic Health), Inivata, Natera, AstraZeneca, and Athena; support for attending meetings and travel from Daichi-Sankyo, Eli Lilly, Caris Life Sciences, and Bristol-Myers Squibb; participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca; and a leadership or fiduciary role in National Surgical Adjuvant Breast and Bowel Project Foundation Board and Conquer Cancer Foundation Board. All other authors declare no competing interests.

Data sharing
The data sharing policy is available online at https://www.ndph.ox.ac.uk/data-access.

Acknowledgments
The EBCCTG Secretariat is funded primarily by a project grant from Cancer Research UK, with additional support from core funding to the Clinical Trial Service Unit and the Population Health Research Unit, Nuffield Department of Population Health, University of Oxford from Cancer Research UK, and the UK Medical Research Council. The chief acknowledgment is to the women who took part in these trials and to the trialists who conducted the studies and shared their data. The paper is dedicated to the memory of Aron Goldirsch, who played a pivotal role in the development of the EBCCTG Collaboration and the HERA trial.

References
1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82.
2. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27: 5790–06.

www.thelancet.com/oncology Vol 22 August 2021 1149
3 Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92.

4 Rondom EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673–84.

5 Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–72.

6 Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with or without docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27: 5685–92.

7 Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy/trastuzumab, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377–84.

8 D’Hondt V, Canon JL, Roca L, et al. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup. Eur J Cancer 2019; 122: 91–100.

9 Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273–83.

10 Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12: 236–44.

11 Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M. HER2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update summary. J Oncol Pract 2018; 14: 437–41.

12 Early Breast Cancer Trialists’ Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379: 412–44.

13 Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer. Volume 1: worldwide evidence, 1985–1990. http://www.ctsu.ox.ac.uk/reports/ebtcg/1990/index_html (accessed July 8, 2021).

14 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–713.

15 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386: 1341–52.

16 Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA 2015; 313: 1657–65.

17 Early Breast Cancer Trialists’ Collaborative Group. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37,298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393: 1440–52.

18 Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017; 377: 1836–46.

19 Fehrenbacher L, Cecchini RS, Geyer CE Jr, et al. NSABP B-47/NRG oncology Phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J Clin Oncol 2020; 38: 44–53.

20 Pegram MD, Konecny GE, O’Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739–49.

21 Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017; 389: 1195–205.

22 Martin M, Holmes FA, Fjeldsten B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18: 1688–700.

23 Joensuu H, Fraser J, Wildiers H, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomised clinical trial. JAMA Oncol 2018; 4: 1199–206.

24 Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 2019; 393: 2591–62.

25 Earl HM, Hiller L, Vallier AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019; 393: 826–37.

26 Mavroudis D, Saloustros E, Malamos N, et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol 2015; 26: 1333–40.

27 Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III NAVIGATE trial. J Clin Oncol 2016; 34: 1034–42.

28 von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017; 377: 122–31.

29 Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (Neoadjuvant): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016; 17: 791–800.

30 von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617–28.

31 Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Turnover-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19: 40–50.